| |  Online-Ressource |
|---|
| Verfasst von: | Kasper, Bernd [VerfasserIn]  |
|---|
| | Lehnert, T. [VerfasserIn] |
|---|
| | Bernd, Ludger [VerfasserIn] |
|---|
| | Mechtersheimer, Gunhild [VerfasserIn] |
|---|
| | Goldschmidt, Hartmut [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| | Egerer, Gerlinde [VerfasserIn] |
|---|
| Titel: | High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas |
|---|
| Verf.angabe: | B. Kasper, T. Lehnert, L. Bernd, G. Mechtersheimer, H. Goldschmidt, A.D. Ho and G. Egerer |
|---|
| E-Jahr: | 2004 |
|---|
| Jahr: | 31 May 2004 |
|---|
| Umfang: | 5 S. |
|---|
| Illustrationen: | Diagramme |
|---|
| Fussnoten: | Gesehen am 03.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2004 |
|---|
| Band/Heft Quelle: | 34(2004), 1, Seite 37-41 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established. In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13-59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheath tumor) n=4, synovial sarcoma n=3, liposarcoma n=2, leiomyosarcoma n=2, rhabdomyosarcoma n=1, meningosarcoma n=1). Following chemotherapy and surgery complete remission (CR) (n=9), partial remission (PR) (n=10), stable disease (SD) (n=2) and progressive disease (PD) (n=6) were reached prior HDCT. Different HDCT conditioning regimens were used. One patient died due to cardiac arrest after HDCT. Except hematologic side effects, no WHO grade III-IV complications were observed. Four patients died within 6 months due to PD, disease recurred in another seven patients and led to death, 15 patients are alive with/without disease. The median progression-free survival (PFS) is 12.0 months (range: 0-58), in nine CR patients median PFS is 25.8 months (range: 3-58). Although the role of HDCT in the treatment of sarcomas is not defined, a subgroup of patients who achieved CR before HDCT could benefit from this therapy. |
|---|
| DOI: | doi:10.1038/sj.bmt.1704520 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/sj.bmt.1704520 |
|---|
| | Volltext: https://www.nature.com/articles/1704520 |
|---|
| | DOI: https://doi.org/10.1038/sj.bmt.1704520 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Cell Biology |
|---|
| | general |
|---|
| | Hematology |
|---|
| | Internal Medicine |
|---|
| | Medicine/Public Health |
|---|
| | Public Health |
|---|
| | Stem Cells |
|---|
| K10plus-PPN: | 1780216467 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas / Kasper, Bernd [VerfasserIn]; 31 May 2004 (Online-Ressource)
